SYK: Tyrosine-protein kinase SYK
Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).
- Drugs that act on it: 13
- Approved: 1
- In phases 1 to 3: 12
- Sponsors: 6
Who is on it, and how far along
Every drug ChEMBL records acting on SYK, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 11
- Other 2
Approved1
Phase 32
Phase 29
Phase 11
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Rigel Pharmaceuticals431%
- Gilead Sciences215%
- Asana BioSciences18%
- Calithera Biosciences, Inc18%
- Dermavant Sciences GmbH18%
- Hutchmed18%
| Fostamatinib | Approved | Rigel Pharmaceuticals | Small molecule | Inhibitor | 8 |
| Entospletinib | Phase 3 | Gilead Sciences | Small molecule | Inhibitor | 1 |
| Sovleplenib | Phase 3 | Hutchmed | Small molecule | Inhibitor | 1 |
| Cerdulatinib | Phase 2 | Dermavant Sciences GmbH | Small molecule | Inhibitor | 0 |
| Gusacitinib | Phase 2 | Asana BioSciences | Small molecule | Inhibitor | 0 |
| Lanraplenib | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
| Mivavotinib | Phase 2 | Calithera Biosciences, Inc | Small molecule | Inhibitor | 0 |
| R-112 | Phase 2 | — | Small molecule | Inhibitor | 0 |
| R-333 | Phase 2 | Rigel Pharmaceuticals | Other | Inhibitor | 0 |
| R-343 | Phase 2 | Rigel Pharmaceuticals | Small molecule | Inhibitor | 0 |
| R-348 | Phase 2 | Rigel Pharmaceuticals | Small molecule | Inhibitor | 0 |
| R-406 | Phase 2 | — | Small molecule | Inhibitor | 0 |
| PRT-2607 | Phase 1 | — | Other | Inhibitor | 0 |
- Immunodeficiency 82 with systemic inflammation0.64
- Cutaneous leishmaniasis0.57
- Immunodeficiency disease0.57
- Decreased circulating immunoglobulin concentration0.56
- Autoimmune thrombocytopenic purpura0.52
- Thrombocytopenia0.51
- Colitis0.49
- Exanthem0.48
- Arthritic joint disease0.47
- Rheumatoid arthritis0.41
- Lung carcinoma0.39
- Esophageal adenocarcinoma0.38
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2599, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt P43405, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets